Comparing the current results to its competitors, Apogee Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 6.33 %, recorded in the same quarter.
Apogee Therapeutics Inc , slower than the average decrease reported by the company's competitors of -60.71 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -60.71 %
Apogee Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and biopharmaceutical industries, which are characterized by intense competition and continuous technological advancements. Competitors include major pharmaceutical and biotechnology firms, academic institutions, governmental agencies, and both public and private research organizations. Many competitors possess greater financial resources and expertise in areas such as research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Industry consolidation through mergers and acquisitions can concentrate resources among fewer entities. Additionally, smaller or early-stage companies may pose significant competition, particularly through partnerships with larger firms. Competition also occurs in recruiting personnel, establishing clinical trial sites, patient enrollment, and acquiring complementary technologies. Key factors influencing success include the efficacy, safety, convenience, and presentation of product candidates.
May 15, 2024
Apogee Therapeutics Initiates Phase 2 Clinical Trial of APG777 for Atopic Dermatitis Following Promising Phase 1 Results Apogee Therapeutics recently announced the commencement of dosing in their Phase 2 clinical trial for APG777, a novel subcutaneous, half-life extended anti-IL-13 antibody. This drug is being investigated for the treatment of atopic dermatitis and other inflammatory diseases. The announcement follows the successful conclusion of a Phase 1 study in healthy volunteers, which not only met but exceeded all trial s. Mechanism of Action and Drug Profile APG777 is engineered to inhibit interleukin-13 (IL-13), a cytokine implicated in the inflammatory pathways of atopic dermatitis and other...
May 13, 2024
Apogee Therapeutics Advances Promising Drug Pipeline and Acknowledges Strong First Quarter 2024 Financial Performance: Anticipates Key Data Release for APG777 in Late 2025Apogee Therapeutics, a leading biopharmaceutical company, is making remarkable progress in its pursuit of innovative therapies for patients suffering from debilitating conditions. The company recently announced the initiation of a Phase 2 clinical trial for its flagship drug candidate, APG777, an extended half-life monoclonal antibody designed to target IL-13, in individuals diagnosed with moderate-to-severe atopic dermatitis. Additionally, Apogee Therapeutics reported robust financial results for the first quarter of 2024, highlighting the...
Calidi Biotherapeutics Inc's business model revolves around developing and commercializing innovative cell-based immunotherapies for the treatment of cancer.
Compass Therapeutics Inc operates as a biotechnology company focused on discovering and developing novel antibody therapeutics for the treatment of cancer and autoimmune diseases. Their business model revolves around leveraging their proprietary Targeted Immunomodulation platform to identify and advance multiple antibody candidates through preclinical and clinical development stages.
Cardiol Therapeutics Inc. operates on a business model focused on the research and development of pharmaceutical-grade cannabidiol (CBD) and targeted therapies for cardiovascular diseases. The company aims to leverage its expertise to develop innovative and effective treatments to address unmet medical needs in the field of heart-related conditions.
Dyadic International Inc's business model revolves around developing and licensing proprietary microbial strains and technologies for use in the biopharmaceutical, biofuels, and industrial enzyme industries.
Sources:
Apogee Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Apogee Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
